文献速递乳腺癌放疗放疗物理与技术

乳房切除术后高适形电子束放疗技术的长期疗效

Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-27

本研究回顾性纳入2007至2011年接受乳房切除术后高适形电子束放疗(PMERT)的非转移性乳腺癌女性796例,评估局部区域控制、生存及毒性。中位随访64个月,5年局部区域无复发生存率和总生存率分别为90%和90.9%,急性和长期毒性总体可控。

要点

  • 5年局部区域无复发生存率90%,总生存率90.9%。
  • 急性3级皮肤毒性4.5%,同步化疗与3级毒性增加相关(P<.001)。
  • 长期3级色素沉着/毛细血管扩张/纤维化仅1%,吸烟者发生率更高(P=.06)。

核心结论

  • PMERT技术在局部区域控制和生存方面疗效良好,短期和长期安全性良好。
  • 需要更长期随访以分析慢性心脏事件。

研究设计与样本

  • 回顾性纳入2007至2011年本科室接受乳房切除术后电子束放疗的非转移性乳腺癌女性796例。
  • 急性和晚期毒性采用不良事件通用术语标准3.0版回顾性评估。

主要发现

  • 中位随访64个月(范围6-102个月),5年局部区域无复发生存率为90%(95%CI 88.1%-92.4%)。
  • 5年总生存率为90.9%(95%CI 88.9%-93%)。
  • 早期皮肤毒性1级占58.5%、2级占35.9%、3级占4.5%,同步化疗与3级毒性增加相关(P<.001)。
  • 长期随访中29.8%患者出现暂时或永久性色素沉着、毛细血管扩张或纤维化(1级23.6%、2级5.2%、3级1%),吸烟者发生率更高(P=.06)。
  • 274例(34.4%)接受乳房重建,仅24例(3%)出现1级早期食管炎,仅3例发生缺血性心脏病。

关键数值与推荐

  • 内乳链、锁骨上、锁骨下和腋窝淋巴结分别有85.6%、88.3%、77.9%和14.9%的病例接受治疗。
  • 10.1%为三阴性,18.8%为HER2阳性,24.6%接受新辅助化疗,51.3%有多发病灶,64.6%有至少1个淋巴结受累。

临床怎么用

  • PMERT可作为乳房切除术后胸壁放疗的可选技术,需关注同步化疗时的急性皮肤毒性。
  • 吸烟者长期皮肤毒性发生率更高,应加强戒烟宣教和皮肤随访。
  • 接受蒽环类化疗且照射左胸壁和淋巴结、合并多个心血管危险因素者需关注缺血性心脏病风险。

局限性

  • 回顾性设计,毒性评估基于病历记录。
  • 中位随访64个月,慢性心脏事件随访时间不足。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate locoregional control and survival after mastectomy, as well as toxicity, in patients irradiated by a previously described postmastectomy highly conformal electron beam radiation therapy technique (PMERT). METHODS AND MATERIALS: We included all women irradiated by postmastectomy electron beam radiation therapy for nonmetastatic breast cancer between 2007 and 2011 in our department. Acute and late toxicities were retrospectively assessed using Common Terminology Criteria for Adverse Events version 3.0 criteria. RESULTS: Among the 796 women included, 10.1% were triple-negative, 18.8% HER2-positive, and 24.6% received neoadjuvant chemotherapy (CT). Multifocal lesions were observed in 51.3% of women, and 64.6% had at least 1 involved lymph node (LN). Internal mammary chain, supraclavicular, infraclavicular, and axillary LNs were treated in 85.6%, 88.3%, 77.9%, and 14.9% of cases, respectively. With a median follow-up of 64 months (range, 6-102 months), 5-year locoregional recurrence-free survival and overall survival were 90% (95% confidence interval 88.1%-92.4%) and 90.9% (95% confidence interval 88.9%-93%), respectively. Early skin toxicity was scored as grade 1 in 58.5% of patients, grade 2 in 35.9%, and grade 3 in 4.5%. Concomitant CT was associated with increased grade 3 toxicity (P<.001). At long-term follow-up, 29.8% of patients presented temporary or permanent hyperpigmentation or telangiectasia or fibrosis (grade 1: 23.6%; grade 2: 5.2%; grade 3: 1%), with higher rates among smokers (P=.06); 274 patients (34.4%) underwent breast reconstruction. Only 24 patients (3%) had early esophagitis of grade 1. Only 3 patients developed ischemic heart disease: all had been treated by anthracycline-based CT with or without trastuzumab, all had been irradiated to the left chest wall and LN, and all presented numerous cardiovascular risk factors (2-4 factors). CONCLUSIONS: This study demonstrated the good efficacy of this technique in terms of locoregional control and survival, and good short-term and long-term safety. Longer follow-up is required to analyze chronic cardiac events.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Grellier Adedjouma N, Chevrier M, Fourquet A, et al. Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586961. doi:10.1016/j.ijrobp.2017.01.205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。